Compatibility of 17-α-Estradiol, Betamethasone, Finasteride, Melatonin, Prednicarbate, and Spironolactone in TrichoFoam: A Foaming Vehicle for Personalized Alopecia Treatments

The study evaluates the compatibility of six active pharmaceutical ingredients (APIs) in TrichoFoam™, a foaming vehicle for personalized alopecia treatments. Using HPLC and UHPLC, the stability and efficacy of 17-α-estradiol, betamethasone, finasteride, melatonin, prednicarbate, and spironolactone were assessed. The APIs showed satisfactory compatibility with TrichoFoam™, maintaining stability and efficacy over time, with beyond-use dates ranging from 14 to 180 days depending on the API. The results support TrichoFoam™ as a promising vehicle for delivering multiple APIs in alopecia treatments, potentially enhancing patient adherence and therapeutic outcomes.